[Platinum-based combination chemotherapy for malignant mixed mesodermal tumor of the ovary: a case report].
Malignant mixed mesodermal tumor (MMMT) of the ovary is a rare neoplasm with a dismal prognosis and therapeutic modalities remain an enigma. The present paper describes our experience with an impressive response utilizing a cis-platinum based combination chemotherapy in a 56-year-old female with this disease and a review of the literature. The patient was treated with PAIE therapy following a cytoreductive surgery. Two further courses of a single-agent chemotherapy of cis-platinum were given. A PR was obtained after completion of the third course and tumor markers showed a prompt fall with a tumor response. Nevertheless, no further therapy was performed because of her refusal. She expired 5 months after diagnosis because of tumor progression.
Hamaguchi
K
K
Department of Obstetrics and Gynecology, National Kokura Hospital.
Okura
N
N
Nagasue
N
N
Nishimura
H
H
Yakushiji
M
M
Harataka
J
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012074:Remission Induction
D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide